Hohimer Wealth Management’s Royalty Pharma RPRX Stock Holding History

Hohimer Wealth Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-36,251	Closed	-$1.4M	–	416
2025 Q4	$1.4M	Buy	36,251 +499	+1%	+$19K	0.19%	123
2025 Q3	$1.26M	Buy	35,752 +3,434	+11%	+$124K	0.18%	128
2025 Q2	$1.16M	Sell	32,318 -578	-2%	-$19.1K	0.21%	102
2025 Q1	$1.02M	Sell	32,896 -792	-2%	-$25.1K	0.2%	105
2024 Q4	$859K	Sell	33,688 -111,669	-77%	-$2.96M	0.16%	122
2024 Q3	$4.11M	Buy	145,357 +1,445	+1%	+$40K	0.88%	40
2024 Q2	$3.79M	Buy	+143,912	New	+$3.99M	0.88%	37

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Hohimer Wealth Management's RPRX Position: Q1 2026 in Review

Hohimer Wealth Management sold out of Royalty Pharma (RPRX) in Q1 2026, closing a stake of 36,251 shares — an estimated $1.4M sold.

Hohimer Wealth Management first reported a position in RPRX in Q2 2024 and held it in 7 quarters. The position peaked at $4.11M in Q3 2024. 592 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Hohimer Wealth Management reported no remaining Royalty Pharma position as of Q1 2026 after selling out during the quarter.
Hohimer Wealth Management sold 36,251 Royalty Pharma shares in Q1 2026, an estimated $1.4M.
Hohimer Wealth Management first reported a position in Royalty Pharma in Q2 2024 and held it in 7 quarters.
Hohimer Wealth Management's Royalty Pharma position peaked at $4.11M in Q3 2024.
592 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Hohimer Wealth Management's 13F filing for Q1 2026, filed 1 May 2026.